Emergent BioSolutions to Webcast Presentation at Credit Suisse First Annual
ROCKVILLE, Md. -- April 29, 2013
Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company will
be webcasting its presentation at the Credit Suisse First Annual Antibody Day
in New York on May 10, 2013 at 9:30 AM Eastern. During the presentation, a
member of the company's management team will provide an overview of the
company’s lead clinical development candidate, the TRU-016 ADAPTIR™ (Modular
Protein Technology) therapeutic, as well as a discussion of the company’s
ADAPTIR platform and certain pre-clinical programs based on the ADAPTIR
platform. The webcast of this presentation will be available both live and by
replay, accessible from the Emergent website www.emergentbiosolutions.com
About the ADAPTIR Platform
ADAPTIR bispecific proteins are modular, single chain polypeptides that
comprise two separate binding domains (VL and VH), a hinge segment, and an
effector domain (huFc). They have a differentiated structure from monoclonal
antibodies and can generate a unique signaling response. In addition, ADAPTIR
proteins may mediate complement dependent cytotoxicity and Fc dependent
cytotoxicity, similar to monoclonal antibodies.
ADAPTIR^TM and any and all Emergent BioSolutions Inc. brand, product, service
and feature names, logos and slogans are trademarks or registered trademarks
of Emergent BioSolutions Inc. or its subsidiaries in the United States or
other countries. All rights reserved.
About Emergent BioSolutions Inc.
Emergent BioSolutions is a specialty pharmaceutical company seeking to protect
and enhance life by offering specialized products to healthcare providers and
governments to address medical needs and emerging health threats. Additional
information about us may be found at www.emergentbiosolutions.com.
Follow us on Twitter: @emergentbiosolu.
Emergent BioSolutions Inc.
Robert G. Burrows
Vice President, Investor Relations
Vice President, Corporate Communications
Press spacebar to pause and continue. Press esc to stop.